Heart patient Christian Volpe, a resident of TK, called NYP when the batteries on his LVAD ran dangerously low, putting his life at risk. Nurse practitioner Khristine Orlanes arranged for nearby LVAD patient Robert Bump to bring him fresh batteries. Coincidentally both men returned to NYPH/Columbia for heart transplants in late July and had the chance to meet again. Their transplant surgeries were performed by Drs. Mathew Williams and Hiroo Takayama.
Heart failure patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first to be implanted with the HeartMate® II LVAS (Left Ventricular Assist System)—a miniature mechanical pump that helps weak hearts pump blood—that has now received approval by the FDA as of April 21 for broad use as bridge to transplantation. As part of clinical trials leading to approval, 22 patients received the new device at NewYork-Presbyterian/Columbia—more than any other hospital in the New York area.
Clinical research studies at medical centers, including NewYork-Presbyterian/Columbia, showed the HeartMate® II to be safe and effective, with improved quality of life and survival compared with historical norms for heart-failure patients. In addition, the device is designed to be quieter and more durable than other FDA approved devices.
Dr. Yoshifumi Naka is national co-principal investigator in the DuraHeart Left Ventricular Assist System Bridge-to-Transplant Pivotal Trial for patients awaiting transplant.
NYPH/Columbia begins conducting research under a five year $3.3 million NIH grant entitled, "Biventricular Pacing After Cardiopulmonary Bypass."
Pacing protocols developed under the BiPACS trial are further being tested in patients with right ventricular failure in an effort to expand the benefits of this technology.
The Center for Advanced Cardiac Care provides the most advanced medical and surgical options to patients with heart failure, helping to extend the life and quality of life for end stage heart failure patients.
Mechanical Circulatory Support Therapy In Advanced Heart Failure by Mario C. Deng, MD and Yoshifumi Naka, MD, PhD provides a state-of-the-art overview of mechanical circulatory support devices and their role in the care of patients with advanced heart failure. Perspectives of professional teams cardiologists, cardiac surgeons, nurses, coordinators, social workers, psychologists, and physical therapists are presented along with stories of patients and their families.
Heart attack victim Patrick Savage, FDNY Deputy Chief, suffered multiple cardiac arrests and was resuscitated several times before he was taken to New York Presbyterian Hospital. Dr. Yoshifumi Naka implanted a bi-ventricular assist device (BiVAD) temporarily supporting Savage's ailing heart until he performed triple bypass surgery four days later. Savage walked out of the Hospital on March 6, thanking staff for saving his life.
November 2006 New York magazine's "Best Hospitals" issue, published the week of November 20, ranked NewYork-Presbyterian Hospital, where Columbia's cardiac surgeons implant mechanical assist devices, #1 in the cardiac surgery subspecialty.
NewYork-Presbyterian/Columbia Sets World Record for Number of Heart Transplants in One Year, with 119 surgeries performed.
In The Grateful Heart, Diary of a Heart Transplant, Candace Moose chronicles her sudden illness and eventual heart transplant, performed by Yoshifumi Naka, MD, after travel vaccinations triggered a typically fatal autoimmune disease.
NYPH/Columbia researchers begin participating in a $17 million NIH-funded study (SCCOR) investigating the most significant challenges associated with the use of LVADs — infection, coagulation, and neurological events. In one arm of this trial doctors are studying stem cell therapy combined with LVADs as a way to speed the recovery of the native heart.
This issue of NewYork-Presbyterian Heart, written for healthcare professionals, focuses on angiogensis research, LVADs for heart failure, ablation pof arrhythmias, and low-dose statins.
The third issue of the Assist Newsletter focuses on the Mechanical Circulatory Assist Program at NYPH/Columbia, including its role in establishing destination therapy as a viable option for cardiac assist devices. The Heart Hope Initiative is a collaboration between leading heart centers committed to advancing clinical outcomes associated with mechanical circulatory assist devices and other advanced therapies in the treatment of heart failure.
NYPH/Columbia was the principal investigating site for the multicenter REMATCH trial (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure), using the vented electric HeartMate LVAD. This $7 million NIH-funded study was the first comprehensive assessment of mechanical circulatory assistance as a form of destination therapy. The study found that use of the implanted heart pump more than doubled the likelihood that terminally ill heart failure patients would be alive at the end of the year. As a result of the REMATCH trial, LVADs were approved as destination therapy for nontransplantable patients by the Centers for Medicare and Medicaid Services (CMS) in October 2003.
NYPH/Columbia also participated in the initial clinical evaluation of the Thoratec HeartMate pneumatic and vented electric devices leading to their FDA approval in 1994 and 1998.